Stockscreener 앱 받기
1,109.94
3.72%
39.78
시간 외 거래:
1109.63
-0.31
-0.03%
전일 마감가:
$1,070.16
열려 있는:
$1075.825
하루 거래량:
4.18M
Relative Volume:
1.10
시가총액:
$1.05T
수익:
$59.42B
순이익/손실:
$18.41B
주가수익비율:
54.89
EPS:
20.2197
순현금흐름:
$6.44B
1주 성능:
+7.76%
1개월 성능:
+34.46%
6개월 성능:
+55.52%
1년 성능:
+47.01%
1일 변동 폭
$1,073.25
$1,111.11
1주일 범위
$1,026.25
$1,111.11
52주 변동 폭
$623.78
$1,111.11
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,109.94 | 957.81B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.67 | 496.44B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
231.80 | 405.63B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
130.26 | 242.80B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
105.66 | 249.20B | 63.90B | 19.05B | 13.05B | 7.5596 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-10 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
LILLY ENDOWMENT INC Adjusts Holdings in Eli Lilly and Co - GuruFocus
LILLY ENDOWMENT INC Reduces Stake in Eli Lilly and Co - GuruFocus
Top analyst drops jaw-dropping price target on Eli Lilly stock - Yahoo Finance
Eli Lilly switches from Big 3 PBM to alternative transparent rival - Healthcare Brew
Eli Lilly’s $1 Trillion Cap: How the Pharma Giant Shattered Healthcare’s Ceiling - Investing.com
Lilly Redefines the Pharma Mega-Blockbuster - BioSpace
Eli Lilly’s new campaign depicts ups and downs of Alzheimer’s - Brand Innovators
Eli Lilly & Company (LLY) favors rally targeting 1188 - FXStreet
Redditors Are Buying Eli Lilly And Co (LLY) Ahead of Potential End of AI Trade. Here’s Why - Yahoo Finance
A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling - MarketBeat
Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30% - simplywall.st
How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals? - Yahoo Finance
Moneycontrol Pro Panorama | Lessons from Eli Lilly in corporate longevity - Moneycontrol
Major Shareholder Cashes Out Big on Eli Lilly & Co Stock! - TipRanks
Eli Lilly Joins the Trillion-Dollar Club, Powered by Blockbuster Weight-Loss Drugs - NAI500
Lilly to highlight breast cancer treatment advances at SABCS 2025 - Investing.com
Health Care Stocks Edge Up As Biotech Shines And Eli Lilly Gets A Nod - Finimize
Inside Eli Lilly’s Alzheimer’s campaign blitz during holiday season - Campaign US
GLP-1 boom makes Eli Lilly the first $1 trillion pharma company - eMarketer
Lilly to present data from two phase 3 studies of Jaypirca in CLL at ASH By Investing.com - Investing.com South Africa
Eli Lilly’s Becomes Pharma’s First $1 Trillion Company - Oncodaily
Novo Nordisk stumbles against Eli Lilly in GLP-1 drug battle. Which stock is the best buy from here? - CNBC
Eli Lilly (LLY) to Present Key Findings on Jaypirca at Hematology Meeting - GuruFocus
Lilly to present data from two phase 3 studies of Jaypirca in CLL at ASH - Investing.com
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting - Eli Lilly and Company
Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club - Yahoo Finance
Eli Lilly (LLY) Target Price Raised by Morgan Stanley to $1290 | LLY Stock News - GuruFocus
Eli Lilly Gets A Market Share Edge In The GLP-1 Race - Finimize
Eli Lilly, Novo Nordisk and Waltz Health collaborate on access to obesity drugs - Healthcare Finance News
Price Target on Eli Lilly Stock (LLY) Raised to $1,300 at Bernstein - TipRanks
Bernstein Raises Price Target for Eli Lilly (LLY) Amid Outperfor - GuruFocus
Eli Lilly soars to historic $1 trillion valuation first - Rolling Out
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity - Benzinga
Bernstein SocGen reiterates Eli Lilly stock rating with $1,300 price target - Investing.com Australia
Eli Lilly Becomes First Trillion-Dollar Health Company | Health | rochsent.com - The Rochester Sentinel
Lilly hits trillion-dollar valuation as GLP-1 era peaks - statnews.com
Eli Lilly Becomes First Trillion-Dollar Health Company - mydailyrecord.com
Getting Big by Selling Slim – Eli Lilly’s Rise to $1 Trillion - Carson Group
Bernstein raises Eli Lilly stock price target to $1,300 on Orforglipron launch - Investing.com India
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally - Yahoo Finance
Stock Movers: Alphabet, Eli Lilly, RTX - Bloomberg.com
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in - Nasdaq
Morgan Stanley raises Eli Lilly stock price target to $1,290 on GLP-1 market growth - Investing.com
Eli Lilly stock falls, Biogen rises after Novo’s Alzheimer’s trial failure - Investing.com
Eli Lilly Stock Surges 33% in 2025, Tops $1 Trillion Market Cap - TIKR.com
Eli Lilly: Moving To 'Strong Buy' Rating On Revenue Growth Beyond Zepbound (NYSE:LLY) - Seeking Alpha
Eli Lilly & Co. (LLY) Stock: Surges as Company Hits Historic $1 Trillion Market Cap - CoinCentral
These Stocks Are Moving the Most Today: Tesla, Alphabet, Strategy, Eli Lilly, and More - MSN
Bernstein Adjusts PT on Eli Lilly and Co. to $1,300 From $1,100, Maintains Outperform Rating - MarketScreener
Lilly becomes first $1trn+ pharma company - pharmaphorum
Nobel laureate Carolyn Bertozzi to rejoin Lilly board - Endpoints News
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.30%
자본화:
|
볼륨(24시간):